// App-Quantinova.ai

e12024 : Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer.

Researchers

Presenter

  • Maria Cristina Aguilar Martinez

Principal Investigators

  • Claudia Arce-Salinas

  • Juan Antonio Matus

  • Enrique Bargallo-Rocha

  • Robin Shaw-Dulin

  • Hector Maldonado

  • Leticia Mendoza-Galindo

  • Victor Perez-Sanchez

Medical Centers

  • Instituto Nacional de Cancerologia - INCAN, Mexico City, Mexico

  • Instituto Nacional de Cancerologia, Mexico City, MexicoInstituto Nacional de Cancerologia, Zacatecas, Mexico

Locations

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Doxorubicin

  • Paclitaxel

  • Cisplatin

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved